Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
additional information
-
homology modeling of the three-dimensional protein structure, overview
drug target
-
galactose-1-phosphate uridyltransferase (GALT) provides immune protection in the murine model, and confers partial cross protection against heterologous APP sevorars. The enzyme is an effective cross-protective antigen, which can be used as a potential vaccine candidate against multiple Actinobacillus leuropneumoniae serotypes. An in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provides immunoprotection against serovar 1 strain MS71
drug target
-
galactose-1-phosphate uridyltransferase (GALT) provides immune protection in the murine model, and confers partial cross protection against heterologous APP sevorars. The enzyme is an effective cross-protective antigen, which can be used as a potential vaccine candidate against multiple Actinobacillus leuropneumoniae serotypes. An in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provides immunoprotection against serovar 1 strain MS71
-
evolution
-
GALT belongs to the histidine triad family of transferases
evolution
-
GALT belongs to the histidine triad family of transferases
malfunction
Duarte galactosemia results from partial impairment of galactose-1-phosphate uridylyltransferase
malfunction
-
reduced galactose 1-phosphate uridylyltransferase activity is associated with the genetic disease type I galactosemia. Enzyme-deficiency results in an increase in the cellular concentration of galactose 1-phosphate. The accumulation of this toxic metabolite, combined with aberrant glycoprotein and glycolipid biosynthesis, is likely to be the major factor in molecular pathology
malfunction
a galactose-1 phosphate uridylyltransferase (GALT)-deficient mouse model reveals reduced fertility and growth restriction. Mutant mice experience cerebellar hypoplasia, which may result from the down-regulation of the PI3K/Akt signaling pathway
malfunction
classic galactosemia (CG) is a potentially lethal inborn error of metabolism, if untreated, that results from profound deficiency of galactose-1-phosphate. An uidylyltransferasegalactose-1-phosphate uridylyltransferase-null rat model of CG documentes phenotypes and defines the relationships among three key galactose metabolites in different tissues and across post-natal development
malfunction
classic galactosemia is a potentially lethal disease caused by the dysfunction of galactose 1-phosphate uridylyltransferase
malfunction
galactosemia type I is caused by a deficiency of the galactose-1-phosphate uridylyltransferase enzyme (GALT). Galactosemic patients show accumulation of Gal, Gal-1-P, galactitol, and galactonate and decrease levels of UDP-hexoses, all are responsible of the observed phenotype. Galactosemia type I patients harbor variations along the whole sequence of the GALT gene, most variations are of the missense type and are commonly present in compound heterozygous state
malfunction
genetic defects of human galactose-1-phosphate uridyltransferase (hGALT) and the partial loss of enzyme function result in an altered galactose metabolism with serious long-term developmental impairment of organs in classic galactosemia patients. GALT deficiency (classic galactosemia) leads to an accumulation of galactose-1-phosphate, is associated with a potentially lethal acute hepatotoxic syndrome, unless affected newborns are kept under a galactose-restricted diet. Endogenously synthesized galactose however, can exert chronic cell toxic effects and worsen the prospects of patient son longer terms. Most patients suffer from a cognitive impairment, from speech defects, motor function disturbances, and a hypergonadotropic hypogonadism in female patients. The metabolic induction of galactosemia-like phenotypes in healthy epithelial/neuronal cells can support studies on the molecular pathomechanisms in classic galactosemia, in particular under conditions of low galactose stress and residual GALT activity
malfunction
genetic defects of human galactose-1-phosphate uridyltransferase are responsible for classical galactosemia, a are genetic metabolic disorder that is passed down in an autosomal recessive manner. Classical galactosemia mainly occurs due to reduced activity of the enzyme GALT owing to a single nucleotide change in the galactose-1-phosphate uridylyltransferase gene (GALT; 9p13.3). Low activity of the GALT enzyme results in increased accumulation of galactose-1-phosphate in a variety of tissues resulting in severe clinical representation, including liver dysfunction, cataract formation, vomiting, hepatomegaly, hypotonia, septicemia, weight loss, diarrhea, jaundice, lethargy, bleeding tendencies, and ovarian failure, which vary from patient to patient. Intellectual retardation, and developmental and cognitive defects are also observed in patients with galactosemia
metabolism
-
galactose-1-phosphate uridylyltransferase is a key enzyme in the Leloir pathway, the main route for galactose metabolism in red algae
metabolism
-
the enzyme catalyzes a critical step in the Leloir pathway, overview
metabolism
-
the enzyme catalyzes a critical step in the Leloir pathway, overview
metabolism
the enzyme catalyzes a pivotal step in the Leloir pathway of galactose metabolism, overview
metabolism
enzyme in the Leloir pathway
metabolism
enzyme of the Leloir pathway
metabolism
the enzyme is involved in galactose metabolism via the Leloir pathway
metabolism
-
the enzyme catalyzes a pivotal step in the Leloir pathway of galactose metabolism, overview
-
metabolism
-
the enzyme is involved in galactose metabolism via the Leloir pathway
-
physiological function
-
UDPGal is an important substrate for agar synthesis in red alga
physiological function
GalT-deficient mice exhibit a subfertility phenotype in adult females and growth restriction in both sexes. The growth potential and the protein levels of the Akt(Thr308), Akt(Ser473), pan-Akt, Pdk1, and Hsp90 proteins are significantly reduced by 62.5%, 60.3%, 66%, 66%, and 50%, respectively in GalT-deficient primary fibroblast cells. Reduced expression of phosphorylated Akt proteins in the mutant cells leads to diminished phosphorylation of Gsk-3b (-74%). Protein expression of BiP and pPten are 276% and 176% higher, respectively in cells with GalT-deficiency. The mRNA abundance of Akt1, Pdpk1, Hsp90aa1 and Pi3kca genes are significantly reduced at least 2.03-, 1.37-, 2.45-, and 1.78fold, respectively in mutant fibroblasts. Both serum-fasted normal and GalT-deficient cells respond to Igf-1-induced activation of Akt phosphorylation at +15 min, but the mutant cells have lower phosphorylation levels. The steady-state protein abundance of Igf-1 receptor is also significantly reduced in mutant cells
physiological function
-
GalT is a preferentially expressed antigen during APP infection
physiological function
-
GalT is a preferentially expressed antigen during APP infection
-